Cargando…
Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHO...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743450/ https://www.ncbi.nlm.nih.gov/pubmed/36518725 http://dx.doi.org/10.1016/j.jacasi.2022.04.009 |
_version_ | 1784848728041979904 |
---|---|
author | Zhang, Xiaochun Hou, Shiqiang Liu, Weijing Chen, Wei Chen, Fadong Ma, Wei Wang, Jian’an Fan, Youqi Wang, Yan Chang, Dong Fu, Hua Cai, Heng Zhang, Yushun Hou, Cody R. Xu, Yawei Zhou, Daxin Ge, Junbo |
author_facet | Zhang, Xiaochun Hou, Shiqiang Liu, Weijing Chen, Wei Chen, Fadong Ma, Wei Wang, Jian’an Fan, Youqi Wang, Yan Chang, Dong Fu, Hua Cai, Heng Zhang, Yushun Hou, Cody R. Xu, Yawei Zhou, Daxin Ge, Junbo |
author_sort | Zhang, Xiaochun |
collection | PubMed |
description | BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHODS: A prospective, multicenter, registry-based study was conducted in 200 NVAF patients with CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack, vascular disease, female sex) scores ≥2. The primary safety endpoint was defined as any serious adverse events. Efficacy was assessed by a primary composite endpoint of hemorrhagic or ischemic stroke, systemic embolism, and cardiac or unexplained death at 1 year of follow-up. RESULTS: The device was implanted in 196 patients, with 1-stop LAA closure combined with atrial fibrillation ablation implemented in 133 patients. The immediate success rate was 100%. There were serious adverse events in 9 patients (4.5%; 95% CI: 1.6%-7.4%), which mainly occurred in 1-stop LAA closure. All pericardial tamponades occurred in 6 patients with 1-stop LAA closure. No patient experienced a major bleeding event or acute device-related thrombus. During the 12-month follow-up period, the risk of the primary composite endpoint was 1.6% (95% CI: 0.3%-4.5%), and statistical noninferiority was achieved (the upper bound of 95% CI: 4.5% < the prespecified maximum annual incidence of 8.0%). Ischemic stroke occurred in 1 patient, 3 patients had incomplete LAA sealing, and no delayed device-related thrombus was found. CONCLUSIONS: LAA closure with the novel disc-like occluder shows high procedural success, satisfactory safety, and encouraging efficacy for stroke prevention in patients with NVAF. Compared with 1-stop LAA closure, single LAA closure may be more tolerable. (A multicenter, single-arm clinical trial to evaluate the efficacy and safety of left atrial appendage system for left atrial appendage occlusion in patients with non-valvular atrial fibrillation; ChiCTR1900023035) |
format | Online Article Text |
id | pubmed-9743450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-97434502022-12-13 Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation Zhang, Xiaochun Hou, Shiqiang Liu, Weijing Chen, Wei Chen, Fadong Ma, Wei Wang, Jian’an Fan, Youqi Wang, Yan Chang, Dong Fu, Hua Cai, Heng Zhang, Yushun Hou, Cody R. Xu, Yawei Zhou, Daxin Ge, Junbo JACC Asia Original Research BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHODS: A prospective, multicenter, registry-based study was conducted in 200 NVAF patients with CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack, vascular disease, female sex) scores ≥2. The primary safety endpoint was defined as any serious adverse events. Efficacy was assessed by a primary composite endpoint of hemorrhagic or ischemic stroke, systemic embolism, and cardiac or unexplained death at 1 year of follow-up. RESULTS: The device was implanted in 196 patients, with 1-stop LAA closure combined with atrial fibrillation ablation implemented in 133 patients. The immediate success rate was 100%. There were serious adverse events in 9 patients (4.5%; 95% CI: 1.6%-7.4%), which mainly occurred in 1-stop LAA closure. All pericardial tamponades occurred in 6 patients with 1-stop LAA closure. No patient experienced a major bleeding event or acute device-related thrombus. During the 12-month follow-up period, the risk of the primary composite endpoint was 1.6% (95% CI: 0.3%-4.5%), and statistical noninferiority was achieved (the upper bound of 95% CI: 4.5% < the prespecified maximum annual incidence of 8.0%). Ischemic stroke occurred in 1 patient, 3 patients had incomplete LAA sealing, and no delayed device-related thrombus was found. CONCLUSIONS: LAA closure with the novel disc-like occluder shows high procedural success, satisfactory safety, and encouraging efficacy for stroke prevention in patients with NVAF. Compared with 1-stop LAA closure, single LAA closure may be more tolerable. (A multicenter, single-arm clinical trial to evaluate the efficacy and safety of left atrial appendage system for left atrial appendage occlusion in patients with non-valvular atrial fibrillation; ChiCTR1900023035) Elsevier 2022-09-06 /pmc/articles/PMC9743450/ /pubmed/36518725 http://dx.doi.org/10.1016/j.jacasi.2022.04.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Research Zhang, Xiaochun Hou, Shiqiang Liu, Weijing Chen, Wei Chen, Fadong Ma, Wei Wang, Jian’an Fan, Youqi Wang, Yan Chang, Dong Fu, Hua Cai, Heng Zhang, Yushun Hou, Cody R. Xu, Yawei Zhou, Daxin Ge, Junbo Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title | Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title_full | Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title_fullStr | Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title_full_unstemmed | Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title_short | Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation |
title_sort | percutaneous left atrial appendage closure with a novel laa occluder for stroke prevention in atrial fibrillation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743450/ https://www.ncbi.nlm.nih.gov/pubmed/36518725 http://dx.doi.org/10.1016/j.jacasi.2022.04.009 |
work_keys_str_mv | AT zhangxiaochun percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT houshiqiang percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT liuweijing percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT chenwei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT chenfadong percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT mawei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT wangjianan percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT fanyouqi percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT wangyan percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT changdong percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT fuhua percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT caiheng percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT zhangyushun percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT houcodyr percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT xuyawei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT zhoudaxin percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation AT gejunbo percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation |